| 0.3635 Data as of 1:06pm ET |  +0.0136 / +3.89%Today’s Change | 0.28 Today|||52-Week Range 0.81 | +17.26% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $41.8M |
Company Description
Rexahn Pharmaceuticals, Inc. is engaged in developing novel drugs for cancer and central nervous system disorders. Its clinical pipeline features multiple Phase II drugs, including Serdaxin, which is a therapy for treating depression, and potentially Parkinson's disease and Alzheimer's disease; Zoraxel, which is a central nervous system-based therapy for treating sexual dysfunction; and Archexin AKT-inhibitor therapy for treating various cancers, such as pancreatic cancer, renal cell carcinoma, glioblastoma, and cancers of the ovary and stomach. The company was founded on March 19, 2001 by Chang Ho Ahn and is headquartered in Rockville, MD.
Employees
Shareholders
| Mutual fund holders | 3.18% |
| Individual stakeholders | 16.58% |
| Other institutional | -0.65% |
Top Executives
| Chang Ho Ahn, PhD | Chairman & Chief Scientist |
| Rakesh Soni, MBA | President & Chief Operating Officer |
| Peter David Suzdak, PhD | Chief Executive Officer |
| Tae Heum Jeong, PhD | Chief Financial Officer, Secretary & Senior VP |
.
